BioCapital
Filter News
Found 41,883 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
5/8/2023
Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development.
-
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
5/8/2023
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress.
-
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
5/8/2023
Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.
-
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
5/8/2023
Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.
-
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
5/8/2023
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2023 financial results after the close of the U.S. financial markets on Monday, May, 15th , 2023.
-
Altimmune to Participate at Two Upcoming Investor Conferences - May 8, 2023
5/8/2023
Altimmune, Inc. today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
5/8/2023
Biosion USA , Inc. today announced the upcoming presentation of discovery and development data for BSI-038, an anti-CD40 agonistic antibody at the PEGS Boston conference to be held from May 15 to 19, 2023.
-
REGENXBIO to Participate in Upcoming Investor Conferences - May 8, 2023
5/8/2023
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences.
-
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
5/8/2023
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the first quarter of 2023.
-
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
5/5/2023
Aditxt®, Inc. today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases.
-
FDA Roundup: May 05, 2023
5/5/2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
5/5/2023
Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board has appointed Dr Alessandro Riva, MD, as the Company’s new Chairman and CEO to accelerate the development of its innovative immunotherapy portfolio.
-
Owens & Minor Reports First Quarter 2023 Financial Results
5/5/2023
Owens & Minor, Inc. reported financial results for the first quarter ended March 31, 2023.
-
Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial
5/4/2023
Alphyn Biologics announced positive results today from the pediatric population enrolled in its Phase 2a clinical trial of AB-101a, a novel topical candidate for mild-to-moderate atopic dermatitis (AD), at the 22nd European Society for Pediatric Dermatology Congress (ESPD).
-
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
5/4/2023
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.
-
Vanda Pharmaceuticals Announces Presentations at DDW 2023
5/4/2023
Vanda Pharmaceuticals Inc. announced participation at Digestive Disease Week 2023, to be held in Chicago, IL and online from May 6-9, 2023.
-
Novavax to Participate in the BofA Securities 2023 Health Care Conference
5/4/2023
Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that it will participate in the BofA Securities 2023 Health Care Conference.
-
OpGen Announces Closing of $3.5 Million Public Offering
5/4/2023
OpGen, Inc. announced the closing of its previously announced public offering of an aggregate of 4,495,825 shares of its common stock and common stock purchase warrants to purchase up to 4,495,825 shares of common stock at a combined public offering price of $0.7785 per share and accompanying warrant.
-
NextCure Provides Business Update and Reports First Quarter 2023 Financial Results
5/4/2023
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases provided a business update and reported first quarter 2023 financial results.